Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 8/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 8/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29872221 | 0.90 | DPP4 (0.52) | NMUR2NMUR1EPHA2MALT1OPRM1 | |
| SCHEMBL9450499 | 0.88 | EPHA2 (0.50) | NMUR2NMUR1EPHA2MALT1OPRM1 | |
| SCHEMBL9450497 | 0.88 | DPP4 (0.47) | NMUR2NMUR1EPHA2MALT1OPRM1 | |
| SCHEMBL1370327 | 0.86 | CTRB1 (0.42) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL9450494 | 0.86 | EPHA2 (0.48) | NMUR2NMUR1EPHA2MALT1OPRM1 | |
| SCHEMBL7759489 | 0.83 | MAPK8 (0.45) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL7759499 | 0.83 | MAPK8 (0.45) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31289578 | 0.83 | OPRM1 (0.57) | NMUR2NMUR1EPHA2OPRM1OPRK1 | |
| SCHEMBL31473044 | 0.83 | NMUR2 (0.58) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL9450487 | 0.82 | CMA1 (0.47) | NMUR2NMUR1EPHA2MALT1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | MAPK8 4021/4885MAPK9 2837/4885MAPK10 3617/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | MAPK8 4021/4885MAPK9 2837/4885MAPK10 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.